Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study

摘要

For patients with multiple myeloma (MM) that relapsed after treatment with bortezomib- and lenalidomide-based regimens, there were no other treatment options in Korea until 2016. Thalidomide plus a dexamethasone-based regimen is one of the treatment options for patients with relapsed/refractory MM, even after treatment with prior immunomodulatory agents, including thalidomide and lenalidomide.